ARIAD Pharma (ARIA) Posts Q2 Loss of 30c/Share

ARIAD Pharma (NASDAQ: ARIA) reported Q2 EPS of ($0.30), $0.01 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $12.1 million versus the consensus estimate of $13.65 million.

Net product revenues from sales of Iclusig were $11.9 million for the quarter ended June 30, 2014. Net product revenues for the quarter include Iclusig revenues of $7.9 million in the U.S. and $4.0 million in Europe. Net revenues reported exclude $3.6 million related to the following items:

• Deferred revenue of $1.3 million in the U.S., representing Iclusig inventory on hand at our specialty pharmacy as of June 30, 2014 but not yet shipped to patients as of the end of the quarter.
• Shipments of $2.3 million of Iclusig to patients in France during the second quarter ($16.8 million cumulatively through June 30, 2014). We will record revenue related to cumulative shipments to patients in France upon completion of pricing and reimbursement negotiations, net of any amounts that will be refunded to the French health authorities based on the results of such negotiations. We now anticipate that such negotiations will be completed in the first half of 2015.

For earnings history and earnings-related data on ARIAD Pharma (ARIA) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c